Peak Width of Skeletonized Mean Diffusivity as Neuroimaging Biomarker in Cerebral Amyloid Angiopathy

References

1. 1.↵
   1. Charidimou A,
   2. Gang Q,
   3. Werring DJ

   . Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012;83:124–37 doi:10.1136/jnnp-2011-301308 pmid:22056963

   Abstract/FREE Full Text
2. 2.↵
   1. Planton M,
   2. Saint-Aubert L,
   3. Raposo N, et al

   . High prevalence of cognitive impairment after intracerebral hemorrhage. PLoS One 2017;12:e01778886 doi:10.1371/journal.pone.0178886 pmid:28570698

   CrossRefPubMed
3. 3.↵
   1. Boyle PA,
   2. Yu L,
   3. Nag S, et al

   . Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 2015;85:1930–36 doi:10.1212/WNL.0000000000002175 pmid:26537052

   CrossRefPubMed
4. 4.↵
   1. Heinen R,
   2. Vlegels N,
   3. de Bresser J

   , et al. The cumulative effect of small vessel disease lesions is reflected in structural brain networks of memory clinic patients. Neuroimage Clin 2018;19:963–69 doi:10.1016/j.nicl.2018.06.025 pmid:30003033

   CrossRefPubMed
5. 5.↵
   1. O’Sullivan M,
   2. Jones DK,
   3. Summers PE, et al

   . Evidence for cortical “disconnection” as a mechanism of age-related cognitive decline. Neurology 2001;57:632–38 doi:10.1212/wnl.57.4.632 pmid:11524471

   Abstract/FREE Full Text
6. 6.↵
   1. Martinez-Ramirez S,
   2. Greenberg SM,
   3. Viswanathan A

   . Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimers Res Ther 2014;6:1–7 doi:10.1186/alzrt263 pmid:24987468

   CrossRefPubMed
7. 7.↵
   1. Charidimou A,
   2. Ni J,
   3. Ramirez Martinez S, et al

   . Cortical superficial siderosis in memory clinic patients: further evidence for underlying cerebral amyloid angiopathy. Cerebrovasc Dis 2016;41:156–62 doi:10.1159/000442299 pmid:26751369

   CrossRefPubMed
8. 8.↵
   1. Smith EE,
   2. Gurol ME,
   3. Eng JA, et al

   . White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606–12 doi:10.1212/01.wnl.0000142966.22886.20 pmid:15534243

   Abstract/FREE Full Text
9. 9.↵
   1. Xiong L,
   2. Van Veluw SJ,
   3. Bounemia N, et al

   . Cerebral cortical microinfarcts on magnetic resonance imaging and their association with cognition in cerebral amyloid angiopathy. Stroke 2018;49:2330–36 doi:10.1161/STROKEAHA.118.022280 pmid:30355109

   CrossRefPubMed
10. 10.↵
    1. Charidimou A,
    2. Boulouis G,
    3. Gurol ME, et al

    . Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 2017;140:1829–50 doi:10.1093/brain/awx047 pmid:28334869

    CrossRefPubMed
11. 11.↵
    1. Reijmer YD,
    2. Fotiadis P,
    3. Martinez-Ramirez S, et al

    . Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain 2015;138:179–88 doi:10.1093/brain/awu316 pmid:25367025

    CrossRefPubMed
12. 12.↵
    1. Charidimou A,
    2. Boulouis G,
    3. Haley K, et al

    . White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2016;86:505–11 doi:10.1212/WNL.0000000000002362 pmid:26747886

    Abstract/FREE Full Text
13. 13.↵
    1. Baykara E,
    2. Adam R,
    3. Tuladhar AM, et al

    . A novel imaging marker for small vessel disease based on skeletonization of white matter tracts and diffusion histograms. Ann Neurol 2016;40:581–92 doi:10.1002/ana.24758 pmid:27518166

    CrossRefPubMed
14. 14.↵
    1. Petersen RC

    . Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–94 doi:10.1111/j.1365-2796.2004.01388.x pmid:15324362

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Linn J,
    2. Halpin A,
    3. Demaerel P, et al

    . Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74:1346–50 doi:10.1212/WNL.0b013e3181dad605 pmid:20421578

    Abstract/FREE Full Text
16. 16.↵
    1. Crum RM,
    2. Anthony JC,
    3. Bassett SS, et al

    . Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386–91 doi:10.1001/jama.1993.03500180078038 pmid:8479064

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Weintraub S,
    2. Salmon D,
    3. Mercaldo N, et al

    . The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009;23:91–101 doi:10.1097/WAD.0b013e318191c7dd pmid:19474567

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Corrigan JD,
    2. Hinkeldey NS

    . Relationships between parts A and B of the Trail Making Test. J Clin Psychol 1987;43:402–09 doi:10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E pmid:3611374

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Joy S,
    2. Kaplan E,
    3. Fein D

    . Speed and memory in the WAIS-III Digit Symbol-Coding subtest across the adult lifespan. Arch Clin Neuropsychol 2004;19:759–67 doi:10.1016/j.acn.2003.09.009 pmid:15288329

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Sánchez-Cubillo I,
    2. Periáñez JA,
    3. Adrover-Roig D, et al

    . Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009;15:438–50 doi:10.1017/S1355617709090626 pmid:19402930

    CrossRefPubMed
21. 21.↵
    1. Brandt J

    . The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991;5:125–42 doi:10.1080/13854049108403297

    CrossRef
22. 22.↵
    1. Wechsler D

    . Wechsler Memory Scale-Revised Manual. Harcourt Brace Jovanovich; 1987
23. 23.↵
    1. Mack WJ,
    2. Freed DM,
    3. Williams BW, et al

    . Boston Naming Test: shortened versions for use in Alzheimer’s disease. J Gerontol 1992;47:P154–58 doi:10.1093/geronj/47.3.p154 pmid:1573197

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Tombaugh T,
    2. Kozak J,
    3. Rees L

    . Normative data stratified by age and education for two measures of verbal fluency FAS and animal naming. Arch Clin Neuropsychol 1999;14:167–77 pmid:14590600

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Fastenau PS,
    2. Denburg NL,
    3. Mauer BA

    . Parallel short forms for the Boston Naming Test: psychometric properties and norms for older adults. J Clin Exp Neuropsychol 1998;20:828–34 doi:10.1076/jcen.20.6.828.1105 pmid:10484693

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Tombaugh T

    . Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–14 doi:10.1016/S0887-6177(03)00039-8 pmid:15010086

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Wardlaw JM,
    2. Smith EE,
    3. Biessels GJ, et al

    . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38 doi:10.1016/S1474-4422(13)70124-8 pmid:23867200

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Greenberg SM,
    2. Vernooij MW,
    3. Cordonnier C, et al

    . Cerebral microbleeds: a field guide to their detection and interpretation. Lancet Neurol 2009;8:165–74 doi:10.1016/S1474-4422(09)70013-4 pmid:19161908

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Charidimou A,
    2. Linn J,
    3. Vernooij MW, et al

    . Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 2015;138:2126–39 doi:10.1093/brain/awv162 pmid:26115675

    CrossRefPubMed
30. 30.↵
    1. Potter GM,
    2. Chappell FM,
    3. Morris Z, et al

    . Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis 2015;39:224–31 doi:10.1159/000375153 pmid:25823458

    CrossRefPubMed
31. 31.↵
    1. Fotiadis P,
    2. van Rooden S,
    3. van der Grond J, et al

    . Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol 2016;15:811–19 doi:10.1016/S1474-4422(16)30030-8 pmid:27180034

    CrossRefPubMed
32. 32.↵
    1. Deary IJ,
    2. Ritchie SJ,
    3. Muñoz Maniega S, et al

    . Brain peak width of skeletonized mean diffusivity (PSMD) and cognitive function in later life. Front Psychiatry 2019;10:524 doi:10.3389/fpsyt.2019.00524 pmid:1402877

    CrossRefPubMed
33. 33.↵
    1. Lam BY,
    2. Leung KT,
    3. Yiu B, et al

    . Peak width of skeletonized mean diffusivity and its association with age-related cognitive alterations and vascular risk factors. Alzheimers Dement (Amst) 2019;11:721–29 doi:10.1016/j.dadm.2019.09.003 pmid:31700990

    CrossRefPubMed
34. 34.↵
    1. Low A,
    2. Mak E,
    3. Stefaniak JD, et al

    . Peak width of skeletonized mean diffusivity as a marker of diffuse cerebrovascular damage. Front Neurosci 2020;14:238 doi:10.3389/fnins.2020.00238 pmid:32265640

    CrossRefPubMed
35. 35.↵
    1. Schouten TM,
    2. de Vos F,
    3. van Rooden S, et al

    . Multiple approaches to diffusion magnetic resonance imaging in hereditary cerebral amyloid angiopathy mutation carriers. J Am Heart Assoc 2019;8:e011288 doi:10.1161/JAHA.118.011288 pmid:30717612

    CrossRefPubMed
36. 36.↵
    1. Wei N,
    2. Deng Y,
    3. Yao L, et al

    . A neuroimaging marker based on diffusion tensor imaging and cognitive impairment due to cerebral white matter lesions. Front Neurol 2019;10:1–7 doi:10.3389/fneur.2019.00081 pmid:30814973

    CrossRefPubMed
37. 37.↵
    1. McCreary CR,
    2. Beaudin AE,
    3. Subotic A, et al

    . Cross-sectional and longitudinal differences in peak skeletonized white matter mean diffusivity in cerebral amyloid angiopathy. Neuroimage Clin 2020;27:102280 doi:10.1016/j.nicl.2020.102280 pmid:32521475

    CrossRefPubMed
38. 38.↵
    1. Viswanathan A,
    2. Greenberg SM

    . Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011;70:871–80 doi:10.1002/ana.22516

    CrossRefPubMed
39. 39.↵
    1. Smith EE,
    2. Biessels GJ,
    3. De Guio F, et al

    . Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegeneration. Alzheimers Dement (Amst) 2019;11:191–204 doi:10.1016/j.dadm.2019.01.002 pmid:30859119

    CrossRefPubMed
40. 40.↵
    1. Beaudet G,
    2. Tsuchida A,
    3. Petit L, et al

    . Age-related changes of peak width skeletonized mean diffusivity (PSMD) across the adult lifespan: a multi-cohort study. Front Psychiatry 2020;11:342 doi:10.3389/fpsyt.2020.00342 pmid:32425831

    CrossRefPubMed
41. 41.↵
    1. Salat DH,
    2. Smith EE,
    3. Tuch DS, et al

    . White matter alterations in cerebral amyloid angiopathy measured by diffusion tensor imaging. Stroke 2006;37:1759–64 doi:10.1161/01.STR.0000227328.86353.a7 pmid:16763176

    Abstract/FREE Full Text
42. 42.↵
    1. Finsterwalder S,
    2. Vlegels N,
    3. Gesierich B, et al

    . Small vessel disease more than Alzheimer’s disease determines diffusion MRI alterations in memory clinic patients. Alzheimers Dement 2020:16:504–14 doi:10.1002/alz.12150 pmid:32808747

    CrossRefPubMed
43. 43.↵
    1. van Veluw SJ,
    2. Reijmer YD,
    3. van der Kouwe AJ, et al

    . Histopathology of diffusion imaging abnormalities in cerebral amyloid angiopathy. Neurology 2019;92:43 doi:10.1212/wnl.0000000000007005 pmid:30700595

    Abstract/FREE Full Text
44. 44.↵
    1. Charidimou A,
    2. Martinez-Ramirez S,
    3. Shoamanesh A, et al

    . Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology 2015;84:1206–12 doi:10.1212/WNL.0000000000001398

    CrossRefPubMed